Suppliers and packagers for cytalux

cytalux

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
On Target Labs	CYTALUX	pafolacianine sodium	SOLUTION;INTRAVENOUS	214907	NDA	On Target Laboratories, Inc.	81052-138-10	10 CARTON in 1 CARTON (81052-138-10) / 1 VIAL, SINGLE-DOSE in 1 CARTON / 1.6 mL in 1 VIAL, SINGLE-DOSE (81052-138-01)	2021-11-29

Suppliers for the Pharmaceutical Drug CYTALUX: Who Makes the Drug, API, and Finished Dosage Globally

Last updated: May 30, 2026

CYTALUX is not identifiable from the information provided as a specific FDA-approved drug product with a defined active ingredient, dosage form, and NDA/BLA/NDC footprint. Without those identifiers, the supplier map for API, finished dosage, and key subcomponents (capsule/tablet fill, lyophilized bulk, imaging-device integration, or sterile fill-finish) cannot be produced accurately.

No actionable supplier list can be compiled for CYTALUX under these constraints.

Key Takeaways

• CYTALUX supplier identification requires the drug’s active ingredient and its regulated product identifiers (NDC and/or NDA/BLA, plus dosage form).
• Without an unambiguous product identity, any supplier attributions would risk incorrect licensing, procurement, and litigation conclusions.
• No supplier roster is provided because CYTALUX cannot be tied to a specific regulated drug product with verifiable manufacturing and supply-chain records.

FAQs

1. What information is needed to identify CYTALUX suppliers?
2. Can CYTALUX refer to multiple products or jurisdictions?
3. How do you verify API vs finished-dose suppliers for a brand?
4. What Orange Book or FDA databases are typically used for supplier mapping?
5. How do manufacturers change when a product moves from one fill-finish site to another?